CAR19BCMA CAR-T Cells for the Treatment of R/R Plasma Cell Neoplasms

EARLY_PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

August 1, 2025

Primary Completion Date

August 1, 2026

Study Completion Date

August 1, 2027

Conditions
Relapsed or Refractory Plasma Cell Neoplasms
Interventions
OTHER

CAR19BCMA-T cells

"CAR19BCMA-T cells Each subject will be infused with single dose of CD19BCMA-CAR-T cells. A classic 3+3 dose escalation will be employed. The low dose is 1×10\^6 /kg, the medium dose is 2×10\^6 /kg, and the high dose is 3×10\^6 /kg.~Drug: fludarabine and cyclophosphamide Drug: Fludarabine Fludarabine will be given at a dose of 30 mg/m2/day intravenously (IV) for 3 days prior to the infusion of CD19BCMA-CAR-T cells. Drug: Cyclophosphamide Cyclophosphamide will be given at a dose of 300 mg"

Trial Locations (2)

Unknown

The Four Medical Center of PLA General Hospital, China, Beijing

The Six Medical Center of PLA General Hospital, China, Beijing

All Listed Sponsors
lead

Chinese PLA General Hospital

OTHER